Results 111 to 120 of about 11,369 (213)
Applications of Mathematical Modelling in Oncolytic Virotherapy and Immunotherapy [PDF]
Cancer is a devastating disease that touches almost everyone and finding effective treatments presents a highly complex problem, requiring extensive multidisciplinary research.
Jenner, A., Jenner, Adrianne Lena
core
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances [PDF]
Oncolytic viruses are multifunctional anticancer agents with huge clinical potential, and have recently passed the randomized Phase III clinical trial hurdle.
Relph, KL +4 more
core +1 more source
Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan +9 more
doaj +1 more source
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Oncolytic virotherapy for cancer is an innovative therapeutic option where the ability of a virus to promote cell lysis is harnessed and reprogrammed to selectively destroy cancer cells.
Janice Kim +6 more
core +1 more source
Patient-derived tumoroids and proteomic signatures: tools for early drug discovery
Onco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties.
Hélène Lê +11 more
doaj +1 more source
Oncolytic virotherapy: the questions and the promise
Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire +3 more sources
This study reports a strategy to overcome immune escape of tumors during viro-immunotherapy due to tumor heterogeneity. We pursued a dual-targeting approach of epidermal growth factor receptor (EGFR) and cellular mesenchymal epithelial transition factor (
Martin A. Boos +8 more
doaj +1 more source
Supplementary Figures 1-6 from Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor ...
Paola Marcato (102530) +3 more
core +1 more source
Editorial: Oncolytic virotherapy
Ahmed Majeed Al-Shammari +2 more
openaire +3 more sources

